Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

Abivax’s COVID-19 study declared Research National Priority by French government

Drug treatment is being investigated in high-risk COVID-19 patients

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

This is a new option for advanced prostate cancer patients in the US

- PMLiVE

GSK signs collaboration deal with Ligand targeting neurological disorders

This is the latest in a string of pipeline deals announced by GSK

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Dear Joe

An open letter to the incoming President of the United States on COVID-19 messaging priorities

- PMLiVE

UPDATED: EU authorises Pfizer/BioNTech’s COVID-19 vaccine

Authorisation closely follows CHMP recommendation

- PMLiVE

EU authorises Aimmune’s peanut allergy treatment Palforzia

Approval in the EU comes nine months after US authorisation

- PMLiVE

CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers

First participant will be vaccinated on 22 December

- PMLiVE

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links